The Bully Pulpit in Action: Cipro and Zevalin
This article was originally published in RPM Report
Executive Summary
Former HHS Secretary Thompson's negotiation of a price discount on Bayer's antibiotic Cipro during the anthrax scare of 2001 is everybody's favorite example of price negotiation in action. The real lesson of that case, though, is that negotiation can pay off for manufacturers. For a less rosy example, consider Biogen Idec's experience with Zevalin.
You may also be interested in...
Favorable Drug Pricing Language In COVID-19 Government Contracts May Backfire for Industry
Pharma has won pricing battles during the pandemic, but doesn’t seem to be winning war as senators on both sides of the aisle question how some drug companies were able to skirt controversial intellectual property ownership issues in COVID-19 drug and vaccine agreements with the US government. IP experts say the biggest harm to the government from the contracting language may not be the pricing concerns but the government’s ability to share leanings from the partnerships with other coronavirus development programs.
Dendreon vs. CMS:Controversy Is Bigger Than One Product
It appeared as though the controversy over the level of efficacy and benefit from the prostate cancer immunotherapy Provenge ended when the drug was approved by FDA at the end of April. The FDA approval may have just been the halfway point in the product's route through government agencies to the commercial market. Now Medicare is questioning whether the government should pay for the new therapy. The CMS decision is just as important to the biopharmaceutical industry as it is to Dendreon.
Putting the Bully in the Bully Pulpit: The Democrats' Plan to Cut Drug Prices
Legislation to force price negotiation under Medicare Part D is likely to end in a stalemate. But manufacturers can't afford to relax: the Democrats plan to turn up the pressure even if a law never passes. First they will compare Part D prices to other benchmarks. Then the bullying begins.